La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Genmab Croissance future

Future contrôle des critères 4/6

Genmab devrait augmenter ses bénéfices et son chiffre d'affaires de 21.1% et de 14.6% par an respectivement. Le BPA devrait croître de de 18.2% par an. Le rendement des capitaux propres devrait être 16.7% dans 3 ans.

Informations clés

21.2%

Taux de croissance des bénéfices

18.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	33.8%
Taux de croissance des recettes	14.6%
Rendement futur des capitaux propres	16.7%
Couverture par les analystes	Good
Dernière mise à jour	20 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Prévisions de croissance des bénéfices et des revenus

CPSE:GMAB - Estimations futures des analystes et données financières antérieures (DKK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	28,911	8,225	7,998	8,601	17
12/31/2025	24,372	6,236	6,071	6,938	23
12/31/2024	20,833	5,278	635	5,823	21
6/30/2024	19,016	5,540	6,515	6,735	N/A
3/31/2024	17,783	5,467	5,358	5,658	N/A
12/31/2023	16,474	4,352	7,004	7,380	N/A
9/30/2023	16,884	4,188	5,687	6,106	N/A
6/30/2023	16,227	4,641	5,634	6,037	N/A
3/31/2023	15,220	5,197	6,196	6,560	N/A
12/31/2022	14,505	5,452	3,595	3,912	N/A
9/30/2022	11,987	5,654	3,480	3,755	N/A
6/30/2022	10,210	3,962	1,964	2,234	N/A
3/31/2022	9,020	2,377	1,349	1,630	N/A
12/31/2021	8,417	2,957	1,976	2,228	N/A
9/30/2021	7,907	2,873	947	1,189	N/A
6/30/2021	7,321	2,513	5,609	5,820	N/A
3/31/2021	10,800	5,585	5,427	5,704	N/A
12/31/2020	10,111	4,758	6,126	6,433	N/A
9/30/2020	11,028	5,649	7,128	7,406	N/A
6/30/2020	10,344	5,656	2,369	2,647	N/A
3/31/2020	5,667	2,363	2,444	2,592	N/A
12/31/2019	5,366	2,166	1,215	1,326	N/A
9/30/2019	3,641	1,528	1,252	1,355	N/A
6/30/2019	3,199	1,170	782	1,248	N/A
3/31/2019	2,935	1,345	729	1,199	N/A
12/31/2018	3,025	1,472	537	1,015	N/A
9/30/2018	2,807	1,424	583	1,062	N/A
6/30/2018	2,532	1,239	796	892	N/A
3/31/2018	2,796	1,286	N/A	1,301	N/A
12/31/2017	2,365	1,104	N/A	1,589	N/A
9/30/2017	2,275	1,159	N/A	1,260	N/A
6/30/2017	2,316	1,354	N/A	1,422	N/A
3/31/2017	1,897	1,215	N/A	1,088	N/A
12/31/2016	1,816	1,187	N/A	328	N/A
9/30/2016	1,463	735	N/A	658	N/A
6/30/2016	1,376	686	N/A	591	N/A
3/31/2016	1,196	535	N/A	358	N/A
12/31/2015	1,133	764	N/A	311	N/A
9/30/2015	774	443	N/A	70	N/A
6/30/2015	768	463	N/A	23	N/A
3/31/2015	710	420	N/A	98	N/A
12/31/2014	850	301	N/A	133	N/A
9/30/2014	851	292	N/A	110	N/A
6/30/2014	729	138	N/A	-31	N/A
3/31/2014	751	138	N/A	-108	N/A
12/31/2013	664	70	N/A	-128	N/A
9/30/2013	611	-5	N/A	-150	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de GMAB ( 21.1% par an) est supérieure au taux d'épargne ( 1% ).

Bénéfices vs marché: Les bénéfices de GMAB ( 21.1% par an) devraient croître plus rapidement que le marché Danish ( 14.1% par an).

Croissance élevée des bénéfices: Les bénéfices de GMAB devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de GMAB ( 14.6% par an) devrait croître plus rapidement que le marché Danish ( 10.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de GMAB ( 14.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de GMAB devrait être faible dans 3 ans ( 16.7 %).

Genmab Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 15%

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 11%

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Provides Earnings Guidance for 2023

Recent updates

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance